Home
Radiopharm Theranostics (ASX:RAD) to start prostate cancer trial
PUBLISHED
2022-07-11
Content
Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari provides an update on the company's portfolio of therapies.